This report comes very early, normally just on the very last days of July. Why? Should we wait for something else during the last days of July??? So all accounting work had to be made in 3 weeks, not in 4 weeks as usual.
They tell that ATH got a patent (16/311,428) from the US Patent and Trademark Office on the
method of treating immunoglobulin light chain amyloidosis. I thought that this would be "a PBT2 patent" because ATH had previously had a PBT2 patent for cardiac light chain amyloidosis. But in this report today, PBT2 is not mentioned, not any zinc chelator.
Something could be happening with PBT2, maybe silence will be over within these 8 days of July???
Ann: Appendix 4C and Quarterly Cash Flow Report, page-4
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
-0.001(11.1%) |
Mkt cap ! $20.98M | |||
| Open | High | Low | Value | Volume |
| 0.5¢ | 0.5¢ | 0.4¢ | $14.55K | 3.241M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 62 | 71906262 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 32338803 | 25 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| ATH (ASX) Chart |